Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pegintron, Rebetol Show Strong Growth in Japan: Schering-Plough
December 19, 2005
- Tyco Healthcare Supports Spread of Laparoscopic Surgery
December 19, 2005
- Pfizer Japan Discusses Restructuring with Labor Union
December 19, 2005
- Osaka Univ. to Develop Training Method for Laparoscopic Surgery
December 19, 2005
- Banyu to Reorganize, Cut 300 Jobs
December 19, 2005
- MEDICAL DEVICE NEWS IN BRIEF
December 19, 2005
- BUSINESS NEWS IN BRIEF
December 19, 2005
- Tissue Engineering and Regenerative Medicine Workshop Held in Kobe
December 19, 2005
- Korosho Proposes Direction for FY2006 NHI Pricing System Reform
December 19, 2005
- Requirements for DPC Hospitals Proposed by Korosho
December 19, 2005
- (Proposed) Direction for FY2006 NHI Pricing System Reform
December 19, 2005
- Pollinosis Much More Common in Boys Under 10 Years of Age
December 19, 2005
- Korosho's Reform Proposal Would Weaken Industry: Mr Crenshaw of PhRMA
December 19, 2005
- Airborne Cedar Pollen Levels Should Be Lower in 2006
December 19, 2005
- Long-listed Drugs' NHI Price Reductions to Negatively Affect State Finances: OPIR
December 19, 2005
- JSCPT Annual Assembly Held in Beppu
December 19, 2005
- EU Directive Effective in Improving Both Speed and Quality: QTJ
December 19, 2005
- R＆D NEWS IN BRIEF
December 19, 2005
- OPINION
December 19, 2005
- SYNPOSIUM
December 19, 2005
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…